Member Info for Bermudashorts

"ANGLE plc (AIM: AGL OTCQX: ANPCY), the specialist medtech company, is pleased to announce that first research use sales of the Parsortix system have been secured" Would have been good to know who the buyer is but excellent news nonetheless. http://www.investegate.co.uk/angle-plc--agl-/rns/parsortix-first-commercial-sales/201512150700060345J/

Not sure whether this has already been posted but Angle are presenting at Biotech Showcase (Jan 11th to 13th) in San Francisco. Biotech Showcase is run in conjunction with the J P Morgan Healthcare Conference which is probably the biggest investor conference in the World. http://www.ebdgroup.com/bts/presenters/prs_comps.php

Redx developing a porcupine inhibitor to target cancers driven by the Wnt pathway. Building up an impressive pre-clinical pipeline in oncology now with at least 6 different inhibitors. Will be interesting to see which make it into the clinic and how that is achieved in terms of funding. http://www.investegate.co.uk/redx-pharma-plc--redx-/rns/fourth-drug-development-candidate/201512030700078030H/

Impressive stuff http://www.investegate.co.uk/angle-plc--agl-/rns/lung-cancer-research-publication/201511170700089140F/ "ANGLE considers the findings reported in the Analyst publication, which, in addition to the clinical work on lung cancer, reports on extensive work that CRUK MI have undertaken on the system since 2012, to be of great importance in demonstrating the potential value of the Parsortix in future cancer care."

http://www.investegate.co.uk/redx-pharma-plc/redx/re-review-on-antimicrobial-resistance/201510231457402924D/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Redx Pharma plc%20Alert

http://www.proactiveinvestors.co.uk/companies/news/116468/

Seems that the FDA Data Monitoring Committee recommended halting the trial after a review of the data that showed that a combination of Synta's drug ganetespib and chemo showed no significant benefit over chemo alone. Great shame for the patients. As for Ergomed, I believe their involvement is restricted to the fact that they performed the completed phase II trial with a reduced fee in return for what I assume would be a small percentage of future revenue. The important point from today's announcement as far as ERGO are concerned is this sentence from the RNS:- "The termination of the study has no impact on the financial position or forecast cash flows of Ergomed" The link to the original announcement is below but essentially the cost to Ergomed has been the amount they reduced their fee by back in 2011. https://www.cambridgenetwork.co.uk/news/ergomed-announces-co-development-agreement-with-synta/

Pontil - that's always good to hear. This must be one of the most under the radar stocks I've ever invested in!

http://www.bullbearings.co.uk/traders.views.php?gid=1&id=880

Good news The granted Canadian patent provides protection over a wide range of uses of the Parsortix technology. Granted patents have already been secured in the United States, China and Australia. Corresponding patent applications have been made worldwide in countries considered to represent substantial markets for Parsortix products. http://www.investegate.co.uk/angle-plc/agl/patent-grant/201510140700351142C/?fe=1&utm_source=FE%20Investegate%20Alerts&utm_medium=Email&utm_content=Announcement%20Alert%20Mail&utm_campaign=Angle PLC%20Alert

http://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-s-co-development-partner-news/201510140700321679C/ "This positive second recommendation from the DSMB is an important milestone since it supports our continuation of the ZoptEC Phase 3 trial in endometrial cancer until its completion. The DSMB recommendation was based upon a comprehensive review of the data on efficacy and safety. We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer."

H1 2015 revenues up 85% to £14.5 million H1 2015 gross profit doubled to £4.2 million H1 2015 EBITDA up 66% Contracts with a value of £15.0 million signed for clinical studies and pharmacovigilance projects in H1 2015 "Our co-development portfolio is maturing and we are looking forward to our partners' late stage clinical data readouts in 2016. We continue to believe that significant value can be generated through focusing our drug development capability on co-development partnerships and as the portfolio expands, Ergomed will be in a position to place more emphasis on this element of the business. Certainly, we are seeing good opportunities in this sector and as one of the few companies taking a shared-risk approach, expect to be one of the leading beneficiaries of this trend going forward. http://www.investegate.co.uk/ergomed-plc--ergo-/rns/ergomed-interim-results-2015/201509290701094986A/

"The Parsortix technology clearly outperforms conventional immune-fluorescent staining. The use of qPCR with the Parsortix system is both highly sensitive and specific and offers the potential for a liquid biopsy (simple blood test) to diagnose ovarian cancer. This would greatly improve the standard of the care that can be offered to women with this condition." ANGLE estimates that the ovarian cancer sales potential for the Parsortix system in Europe and the United States would be in excess of £300 million per annum. http://www.investegate.co.uk/angle-plc--agl-/rns/ovarian-cancer-results/201509280700403168A/

Interview with Andrew Newland following yesterday's RNS https://www.youtube.com/watch?v=n6ZAdQBTE_A

Good news http://www.proactiveinvestors.co.uk/companies/news/111051/ergomed-named-finalist-at-scrip-awards-111051.html

Yes - am pleasantly surprised by the rise. All too often RNS's of this type seem to go unnoticed.

http://www.investegate.co.uk/angle-plc--agl-/rns/prostrate-cancer-study-published-plos-one-journal/201509240700130306A/ "The purity of the cells harvested by the Parsortix system was three times higher than the best antibody-based system studied." "The cells harvested by the Parsortix system are clinically relevant" "the Parsortix system is quicker, easier to use, does not use expensive reagents, captures a wider range of clinically relevant cells and avoids the problems in downstream analysis caused by contaminating magnetic beads."

Interesting collaboration with Horizon to develop the pan-RAF inhibitor program http://www.investegate.co.uk/horizon-dis-grp-plc--hzd-/rns/cancer-research-collaboration-with-redx-pharma/201509030700179222X/

http://www.investegate.co.uk/frenkel-topping-grp--fen-/rns/acquisition-and-board-appointment/201509010703435376X/

Data and Safety Monitoring Board to carry out second interim analysis of Aeterna Zentaris' 3 ZoptEC phase III in endometrial cancer. Study protocol shows the trigger for this second review was about 192 events. Will be very interesting to hear what they recommend - would be amazing if they rec. unblinding!